Showing results (131-140 of 149) with videos related to
Sort By:
Pageof 15
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|April 7, 2010
Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesionsPascale Hubert, Jean Doyen, Xavier Capelle, et al.International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapyNicole Barthelemy-Brichant, Lionel Bosquée, Didier Cataldo, et al.Talanta|May 21, 2014
Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkersMuriel De Bock, Yves Beguin, Pierre Leprince, et al.Contemporary Clinical Trials Communications|May 9, 2018
Aging of monolithic zirconia dental prostheses: Protocol for a 5-year prospective clinical study using ex vivo analysesVinciane Koenig, Claudine P Wulfman, Mathieu A Derbanne, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 20, 2017
FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancerPierre Lovinfosse, Marc Polus, Daniel Van Daele, et al.Haematologica|October 12, 2010
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageEmilie Castermans, Muriel Hannon, Jacques Dutrieux, et al.Patient Education and Counseling|February 14, 2026
Coping with checkpoint inhibitor adverse events: Assisting cancer patients in skills development - insights from the Immuno'Act© pre-experimental pilot studySylvie Streel, Delphine Kirkove, Rémi Gagnayre, et al.Journal of Hematology & Oncology|February 6, 2015
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological SocietyFrédéric Baron, Pierre Zachée, Johan Maertens, et al.Oncotarget|May 15, 2018
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective studySophie Servais, Frédéric Baron, Chantal Lechanteur, et al.Transfusion|June 19, 2013
Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host diseaseMuriel Hannon, Chantal Lechanteur, Sophie Lucas, et al.Pageof 15